Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

  1. Bellmunt, J.
  2. Hussain, M.
  3. Gschwend, J.E.
  4. Albers, P.
  5. Oudard, S.
  6. Castellano, D.
  7. Daneshmand, S.
  8. Nishiyama, H.
  9. Majchrowicz, M.
  10. Degaonkar, V.
  11. Shi, Y.
  12. Mariathasan, S.
  13. Grivas, P.
  14. Drakaki, A.
  15. O'Donnell, P.H.
  16. Rosenberg, J.E.
  17. Geynisman, D.M.
  18. Petrylak, D.P.
  19. Hoffman-Censits, J.
  20. Bedke, J.
  21. Kalebasty, A.R.
  22. Zakharia, Y.
  23. van der Heijden, M.S.
  24. Sternberg, C.N.
  25. Davarpanah, N.N.
  26. Powles, T.
  27. Montrer des auteurs +
Revue:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Année de publication: 2021

Volumen: 22

Número: 4

Pages: 525-537

Type: Article

DOI: 10.1016/S1470-2045(21)00004-8 GOOGLE SCHOLAR